# Appendix

Table A1: Attrition table for the cohort.

|  |  |
| --- | --- |
|  | n |
| Patients approved for study after data extraction | 468 |
| Received systemic treatment | 457 |
| Index year=2017 or 2018 | 424 |
| One year eligibility before Index date | 410 |

**Table A2:** Baseline demographic and clinical characteristics of patients diagnosed with metastatic NSCLC in 2017-2018 by class of 1L treatment\*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Total  N=410** | **Platinum doublet without Bevacizumab n=110** | **Platinum doublet with Bevacizumab n=37** | **Single agent chemotherapy n=15** | **TKI therapy n=101** | **PD-1/PD-L1 inhibitor monotherapy n=136** |
| **Demographic Variables (n, %)** | | | | | | | |
| Age | mean (SD) | 67.47  (9.99) | 67.92  (9.25) | 66.35  (9.27) | 72.67  (11.04) | 67.50  (11.94) | 67.15  (8.92) |
| <65 | 178 (43.4) | 53 (48.2) | 17 (45.9) | 5 (33.3) | 41 (40.6) | 55 (40.4) |
| >=65 | 232 (56.6) | 57 (51.8) | 20 (54.1) | 10 (66.7) | 60 (59.4) | 81 (59.6) |
| Sex | Male | 238 (58.0) | 77 (70.0) | 22 (59.5) | 6 (40.0) | 42 (41.6) | 83 (61.0) |
| Female | 172 (42.0) | 33 (30.0) | 15 (40.5) | 9 (60.0) | 59 (58.4) | 53 (39.0) |
| District | Centre | 263 (64.1) | 68 (61.8) | 28 (75.7) | 9 (60.0) | 64 (63.4) | 90 (66.2) |
| North | 75 (18.3) | 21 (19.1) | 4 (10.8) | 3 (20.0) | 13 (12.9) | 30 (22.1) |
| South | 72 (17.6) | 21 (19.1) | 5 (13.5) | 3 (20.0) | 24 (23.8) | 16 (11.8) |
| Socio-economic status | Low | 160 (39.0) | 59 (53.6) | 15 (40.5) | 6 (40.0) | 40 (39.6) | 38 (27.9) |
| Medium | 92 (22.4) | 14 (12.7) | 12 (32.4) | 2 (13.3) | 23 (22.8) | 39 (28.7) |
| High | 158 (38.5) | 37 (33.6) | 10 (27.0) | 7 (46.7) | 38 (37.6) | 59 (43.4) |
| **Clinical Variables (n, %)** | | | | | | | |
| Deyo-Charlson Comorbidity Index (without malignancy or HIV) | Mean (SD) | 3.75 (3.37) | 3.91 (3.61) | 2.62 (2.62) | 4.60 (3.81) | 3.99 (3.49) | 3.62 (3.17) |
| 0 | 79 (19.3) | 21 (19.1) | 10 (27.0) | 1 (6.7) | 18 (17.8) | 26 (19.1) |
| 1 | 72 (17.6) | 20 (18.2) | 6 (16.2) | 3 (20.0) | 19 (18.8) | 23 (16.9) |
| 2 | 48 (11.7) | 12 (10.9) | 7 (18.9) | 3 (20.0) | 8 (7.9) | 18 (13.2) |
| 3 | 31 (7.6) | 7 (6.4) | 3 (8.1) | 1 (6.7) | 8 (7.9) | 12 (8.8) |
| >=4 | 180 (43.9) | 50 (45.5) | 11 (29.7) | 7 (46.7) | 48 (47.5) | 57 (41.9) |
| Co-morbidities |  | 300 (73.2) | 81 (73.6) | 24 (64.9) | 12 (80.0) | 75 (74.3) | 100 (73.5) |
| Diabetes mellitus | 110 (26.8) | 29 (26.4) | 13 (35.1) | 3 (20.0) | 26 (25.7) | 36 (26.5) |
| Cardiovascular disease | 133 (32.4) | 48 (43.6) | 9 (24.3) | 5 (33.3) | 21 (20.8) | 47 (34.6) |
| Stroke | 10 (2.4) | 4 (3.6) | 1 (2.7) | 0 (0.0) | 0 (0.0) | 4 (2.9) |
| Congestive heart failure | 16 (3.9) | 8 (7.3) | 1 (2.7) | 0 (0.0) | 3 (3.0) | 3 (2.2) |
| Hypertension | 224 (54.6) | 65 (59.1) | 18 (48.6) | 11 (73.3) | 56 (55.4) | 67 (49.3) |
| Chronic kidney disease | 129 (31.5) | 31 (28.2) | 7 (18.9) | 8 (53.3) | 37 (36.6) | 42 (30.9) |
| Chronic obstructive pulmonary disease | 70 (17.1) | 24 (21.8) | 6 (16.2) | 4 (26.7) | 6 (5.9) | 28 (20.6) |
| Smoking | Current or former | 287 (70.0) | 88 (80.0) | 28 (75.7) | 12 (80.0) | 34 (33.7) | 115 (84.6) |
| Unknown | 123 (30.0) | 22 (20.0) | 9 (24.3) | 3 (20.0) | 67 (66.3) | 21 (15.4) |
| Histology | Squamous cell carcinoma | 56 (13.7) | 22 (20.0) | 0 (0.0) | 3 (20.0) | 1 (1.0) | 28 (20.6) |
| Adenocarcinoma | 333 (81.2) | 82 (74.5) | 37 (100.0) | 10 (66.7) | 97 (96.0) | 98 (72.1) |
| Other | 21 (5.1) | 6 (5.5) | 0 (0.0) | 2 (13.3) | 3 (3.0) | 10 (7.4) |
| Location of metastases | Brain | 57 (13.9) | 9 (8.2) | 3 (8.1) | 2 (13.3) | 20 (19.8) | 20 (14.7) |
| Liver | 78 (19.0) | 20 (18.2) | 5 (13.5) | 2 (13.3) | 22 (21.8) | 24 (17.6) |
| Bone | 177 (43.2) | 49 (44.5) | 17 (45.9) | 8 (53.3) | 44 (43.6) | 54 (39.7) |
| Pleura | 120 (29.3) | 32 (29.1) | 10 (27.0) | 4 (26.7) | 36 (35.6) | 35 (25.7) |
| Lymph nodes | 265 (64.6) | 68 (61.8) | 23 (62.2) | 9 (60.0) | 72 (71.3) | 85 (62.5) |
| Adrenal glands | 80 (19.5) | 18 (16.4) | 9 (24.3) | 6 (40.0) | 14 (13.9) | 33 (24.3) |
| ECOG PS | 0-1 | 188 (45.9) | 46 (41.8) | 12 (32.4) | 3 (20.0) | 59 (58.4) | 63 (46.3) |
| 2 | 46 (11.2) | 15 (13.6) | 6 (16.2) | 2 (13.3) | 7 (6.9) | 15 (11.0) |
| >=3 | 24 (5.9) | 3 (2.7) | 0 (0.0) | 1 (6.7) | 6 (5.9) | 13 (9.6) |
| Unknown/missing | 152 (37.1) | 46 (41.8) | 19 (51.4) | 9 (60.0) | 29 (28.7) | 45 (33.1) |
| \*Drug class with N ≤10 is not reported  SD-Standard deviation, TKI-Tyrosine Kinase Inhibitors, PD-1/PD-L1-Programmed Death-1/Programmed Death-Ligand 1, PS-performance score | | | | | | | |